Neurological Disorder Drugs Market on Track for Strong Growth, Estimated to Grow at 6.2% CAGR Through 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Neurological Disorder Drugs Market Through 2025?
The market size for drugs treating neurological disorders has shown significant growth in the past few years. This market is projected to expand from a valuation of $84.6 billion in 2024 to reach $90.09 billion by 2025, with a compound annual growth rate (CAGR) of 6.5%. The notable growth during the historical period is attributed to factors such as a rise in animal testing yielding encouraging results, an increase in available therapeutic treatments, a surge in neurological disorders, governmental support, and an expansion in healthcare spending.

What's the Projected Size of the Global Neurological Disorder Drugs Market by 2029?
In the upcoming years, a significant surge is expected in the neurological disorder drugs market, with its value predicted to reach $114.65 billion in 2029, showcasing a compound annual growth rate (CAGR) of 6.2%. This anticipated growth during the forecast period is due to the proliferation of therapeutic alternatives and personalized treatments, a heightened emphasis on disease-modifying treatments, growing utilization of digital biomarkers, and an increasing incidence of neurological diseases. Notable trends during this period include progression in drug development, advancements in the field of neuroimaging, breakthroughs in genetic research, partnership and licensing deals, and the rising prominence of regenerative medicine.

View the full report here:
https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Top Growth Drivers in the Neurological Disorder Drugs Industry: What's Accelerating the Market?
The anticipated rise in neurological ailments will likely boost the neurological disorder drugs market's growth. Neurological disorders encompass conditions impacting the brain, spinal cord, and nerves due to structural, biochemical, or electrical abnormalities, resulting in an array of symptoms. The uptick in neurological diseases is linked to the aging populace worldwide, increased exposure to environmental, metabolic, and lifestyle-associated risks. Drugs for neurological disorders are essential in managing these intricate conditions, providing symptom relief, decelerating disease evolution, and elevating patients' long-term results. For instance, a projection by the Australian Institute of Health and Welfare, an organization based in Australia, in September 2024 indicates that, between 2023 and 2058, the count of individuals with dementia in Australia is expected to more than double, rising from around 411,100 in 2023 to approximately 849,300 by 2058, affecting about 315,500 men and 533,800 women. Hence, the climbing prevalence of neurological conditions is fueling the expansion of the neurological disorder drugs market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

What Trends Will Shape the Neurological Disorder Drugs Market Through 2029 and Beyond?
The primary players in the neurological disorder drugs industry are concentrating their efforts on the creation of novel Ocrelizumab drug therapies. The intent is to ramp up the effectiveness of treatments, improve patient outcomes, and broaden the range of therapeutic options for those suffering from multiple sclerosis. Ocrelizumab, a humanized monoclonal antibody, is employed as a medicinal drug in dealing with multiple sclerosis (MS), a type of neurological disorder. To exemplify, in February 2024, Ocrevus (Ocrelizumab), a new disease-modifying therapy (DMT) drug for treating multiple sclerosis, was presented in India by Roche Holding AG, a pharmaceutical organization based in Switzerland. Ocrevus has the unique distinction of being the first-ever approved DMT for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS), supported by over a decade of clinical and real-life data. It's a monoclonal antibody that particularly targets CD20-positive B cells, which are suspected to participate in the autoimmune assault on the central nervous system seen in multiple sclerosis. Ocrevus can treat both RRMS and PPMS forms, making it the first medication to gain approval for both types of the disease. It's typically administered intravenously every half a year and has demonstrated its worth by restraining disease activity and delaying the progression of disability as seen in clinical trials.

What Are the Main Segments in the Neurological Disorder Drugs Market?
The neurological disorder drugs market covered in this report is segmented -

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes
2) By Indication: Epilepsy, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegtments:
1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine
2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists
3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics
4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic
5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=17207&type=smp

Which Top Companies are Driving Growth in the Neurological Disorder Drugs Market?
Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

Which Regions Will Dominate the Neurological Disorder Drugs Market Through 2029?
North America was the largest region in the neurological disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17207

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.